Cargando…
Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study
OBJECTIVE: We evaluated the effects of ursodeoxycholic acid (UDCA) on glucagon-like peptide-1 (GLP-1) secretion and glucose tolerance in patients with type 2 diabetes with chronic liver disease. RESEARCH DESIGN AND METHODS: Japanese patients with type 2 diabetes (glycated hemoglobin (HbA1c) levels ≥...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873545/ https://www.ncbi.nlm.nih.gov/pubmed/29607050 http://dx.doi.org/10.1136/bmjdrc-2017-000469 |
_version_ | 1783310050566078464 |
---|---|
author | Shima, Kosuke Robert Ota, Tsuguhito Kato, Ken-ichiro Takeshita, Yumie Misu, Hirofumi Kaneko, Shuichi Takamura, Toshinari |
author_facet | Shima, Kosuke Robert Ota, Tsuguhito Kato, Ken-ichiro Takeshita, Yumie Misu, Hirofumi Kaneko, Shuichi Takamura, Toshinari |
author_sort | Shima, Kosuke Robert |
collection | PubMed |
description | OBJECTIVE: We evaluated the effects of ursodeoxycholic acid (UDCA) on glucagon-like peptide-1 (GLP-1) secretion and glucose tolerance in patients with type 2 diabetes with chronic liver disease. RESEARCH DESIGN AND METHODS: Japanese patients with type 2 diabetes (glycated hemoglobin (HbA1c) levels ≥7.0%) and chronic liver disease were included in this study. Sixteen patients (HbA1c level, 7.2%±0.6%(55.2 mmol/mol)) were randomized to receive 900 mg UDCA for 12 weeks followed by 50 mg sitagliptin add-on therapy for 12 weeks (UDCA-first group; n=8) or 50 mg sitagliptin for 12 weeks followed by 900 mg UDCA add-on therapy for 12 weeks (sitagliptin-first group; n=8). All patients underwent a liquid high-fat meal test before and after 12 or 24 weeks of treatment. RESULTS: The baseline characteristics were similar between the UDCA-first and sitagliptin-first groups. There was a decrease in body weight (72.5±8.4 to 70.6±8.6 kg; P=0.04) and the HbA1c level (7.0%±0.3% to 6.4%±0.5%(53.0 to 46.4 mmol/mol); P=0.01) in the UDCA-first group. The HbA1c level decreased further after sitagliptin administration (6.4%±0.5% to 6.0%±0.4%(46.4 to 42.1 mmol/mol); P<0.01). Although there were no initial changes in the weight and HbA1c level in the sitagliptin-first group, the HbA1c level decreased after UDCA addition (7.1%±1.1% to 6.6%±0.9%(54.1 to 48.6 mmol/mol); P=0.04). UDCA alone increased the area under the curve(0–30) for GLP-1 response (115.4±47.2 to 221.9±48.9 pmol·min/L; P<0.01), but not the glucose-dependent insulinotropic polypeptide response, in the UDCA-first group. CONCLUSIONS: UDCA treatment resulted in a greater reduction in HbA1c levels, and an increased early phase GLP-1 secretion. TRIAL REGISTRATION NUMBER: NCT01337440. |
format | Online Article Text |
id | pubmed-5873545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58735452018-03-30 Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study Shima, Kosuke Robert Ota, Tsuguhito Kato, Ken-ichiro Takeshita, Yumie Misu, Hirofumi Kaneko, Shuichi Takamura, Toshinari BMJ Open Diabetes Res Care Emerging Technologies, Pharmacology and Therapeutics OBJECTIVE: We evaluated the effects of ursodeoxycholic acid (UDCA) on glucagon-like peptide-1 (GLP-1) secretion and glucose tolerance in patients with type 2 diabetes with chronic liver disease. RESEARCH DESIGN AND METHODS: Japanese patients with type 2 diabetes (glycated hemoglobin (HbA1c) levels ≥7.0%) and chronic liver disease were included in this study. Sixteen patients (HbA1c level, 7.2%±0.6%(55.2 mmol/mol)) were randomized to receive 900 mg UDCA for 12 weeks followed by 50 mg sitagliptin add-on therapy for 12 weeks (UDCA-first group; n=8) or 50 mg sitagliptin for 12 weeks followed by 900 mg UDCA add-on therapy for 12 weeks (sitagliptin-first group; n=8). All patients underwent a liquid high-fat meal test before and after 12 or 24 weeks of treatment. RESULTS: The baseline characteristics were similar between the UDCA-first and sitagliptin-first groups. There was a decrease in body weight (72.5±8.4 to 70.6±8.6 kg; P=0.04) and the HbA1c level (7.0%±0.3% to 6.4%±0.5%(53.0 to 46.4 mmol/mol); P=0.01) in the UDCA-first group. The HbA1c level decreased further after sitagliptin administration (6.4%±0.5% to 6.0%±0.4%(46.4 to 42.1 mmol/mol); P<0.01). Although there were no initial changes in the weight and HbA1c level in the sitagliptin-first group, the HbA1c level decreased after UDCA addition (7.1%±1.1% to 6.6%±0.9%(54.1 to 48.6 mmol/mol); P=0.04). UDCA alone increased the area under the curve(0–30) for GLP-1 response (115.4±47.2 to 221.9±48.9 pmol·min/L; P<0.01), but not the glucose-dependent insulinotropic polypeptide response, in the UDCA-first group. CONCLUSIONS: UDCA treatment resulted in a greater reduction in HbA1c levels, and an increased early phase GLP-1 secretion. TRIAL REGISTRATION NUMBER: NCT01337440. BMJ Publishing Group 2018-03-17 /pmc/articles/PMC5873545/ /pubmed/29607050 http://dx.doi.org/10.1136/bmjdrc-2017-000469 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Emerging Technologies, Pharmacology and Therapeutics Shima, Kosuke Robert Ota, Tsuguhito Kato, Ken-ichiro Takeshita, Yumie Misu, Hirofumi Kaneko, Shuichi Takamura, Toshinari Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study |
title | Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study |
title_full | Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study |
title_fullStr | Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study |
title_full_unstemmed | Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study |
title_short | Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study |
title_sort | ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study |
topic | Emerging Technologies, Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873545/ https://www.ncbi.nlm.nih.gov/pubmed/29607050 http://dx.doi.org/10.1136/bmjdrc-2017-000469 |
work_keys_str_mv | AT shimakosukerobert ursodeoxycholicacidpotentiatesdipeptidylpeptidase4inhibitorsitagliptinbyenhancingglucagonlikepeptide1secretioninpatientswithtype2diabetesandchronicliverdiseaseapilotrandomizedcontrolledandaddonstudy AT otatsuguhito ursodeoxycholicacidpotentiatesdipeptidylpeptidase4inhibitorsitagliptinbyenhancingglucagonlikepeptide1secretioninpatientswithtype2diabetesandchronicliverdiseaseapilotrandomizedcontrolledandaddonstudy AT katokenichiro ursodeoxycholicacidpotentiatesdipeptidylpeptidase4inhibitorsitagliptinbyenhancingglucagonlikepeptide1secretioninpatientswithtype2diabetesandchronicliverdiseaseapilotrandomizedcontrolledandaddonstudy AT takeshitayumie ursodeoxycholicacidpotentiatesdipeptidylpeptidase4inhibitorsitagliptinbyenhancingglucagonlikepeptide1secretioninpatientswithtype2diabetesandchronicliverdiseaseapilotrandomizedcontrolledandaddonstudy AT misuhirofumi ursodeoxycholicacidpotentiatesdipeptidylpeptidase4inhibitorsitagliptinbyenhancingglucagonlikepeptide1secretioninpatientswithtype2diabetesandchronicliverdiseaseapilotrandomizedcontrolledandaddonstudy AT kanekoshuichi ursodeoxycholicacidpotentiatesdipeptidylpeptidase4inhibitorsitagliptinbyenhancingglucagonlikepeptide1secretioninpatientswithtype2diabetesandchronicliverdiseaseapilotrandomizedcontrolledandaddonstudy AT takamuratoshinari ursodeoxycholicacidpotentiatesdipeptidylpeptidase4inhibitorsitagliptinbyenhancingglucagonlikepeptide1secretioninpatientswithtype2diabetesandchronicliverdiseaseapilotrandomizedcontrolledandaddonstudy |